A Challenge for Diagnosing Acute Liver Injury with Concomitant/Sequential Exposure to Multiple Drugs: Can Causality Assessment Scales Be Utilized to Identify the Offending Drug?

Drug-induced hepatotoxicity most commonly manifests as an acute hepatitis syndrome and remains the leading cause of drug-induced death/mortality and the primary reason for withdrawal of drugs from the pharmaceutical market. We report a case of acute liver injury in a 12-year-old Hispanic boy, who received a series of five antibiotics (amoxicillin, ceftriaxone, vancomycin, ampicillin/sulbactam, and clindamycin) for cervical lymphadenitis/retropharyngeal cellulitis. Histopathology of the liver biopsy specimen revealed acute cholestatic hepatitis. All known causes of acute liver injury were appropriately excluded and (only) drug-induced liver injury was left as a cause of his cholestasis. Liver-specific causality assessment scales such as Council for the International Organization of Medical Sciences/Roussel Uclaf Causality Assessment Method scoring system (CIOMS/RUCAM), Maria and Victorino scale, and Digestive Disease Week-Japan were applied to seek the most likely offending drug. Although clindamycin is the most likely cause by clinical diagnosis, none of causality assessment scales aid in the diagnosis.

[1]  E. Chiappini,et al.  Antibiotic induced liver injury: what about children? , 2013, Journal of chemotherapy.

[2]  W. Marsden I and J , 2012 .

[3]  C. Stephens,et al.  Causality assessment methods in drug induced liver injury: strengths and weaknesses. , 2011, Journal of hepatology.

[4]  D. Chung,et al.  A case of amoxicillin-induced hepatocellular liver injury with bile-duct damage , 2011, The Korean journal of hepatology.

[5]  Jiezhun Gu,et al.  Characteristics of Idiosyncratic Drug-induced Liver Injury in Children: Results From the DILIN Prospective Study , 2011, Journal of pediatric gastroenterology and nutrition.

[6]  K. Hornbuckle,et al.  Risk of Hepatic Events in Patients Treated with Vancomycin in Clinical Studies , 2011, Drug safety.

[7]  R. Fontana,et al.  Standardization of nomenclature and causality assessment in drug‐induced liver injury: Summary of a clinical research workshop , 2010, Hepatology.

[8]  P. Hayashi Causality assessment in drug-induced liver injury. , 2009, Seminars in liver disease.

[9]  Paul B Watkins,et al.  Biomarkers for the diagnosis and management of drug-induced liver injury. , 2009, Seminars in liver disease.

[10]  M. Dogan,et al.  Ceftriaxone-induced toxic hepatitis. , 2009, World journal of gastroenterology.

[11]  R. Andrade,et al.  Evaluation of Naranjo Adverse Drug Reactions Probability Scale in causality assessment of drug‐induced liver injury , 2008, Alimentary pharmacology & therapeutics.

[12]  O. Kocaman,et al.  Clindamycin-induced acute cholestatic hepatitis. , 2007, World journal of gastroenterology.

[13]  James H. Lewis,et al.  Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. , 2007, Clinics in liver disease.

[14]  A. P. Spencer,et al.  Biliary Sludge and Hyperbilirubinemia Associated with Ceftriaxone in an Adult: Case Report and Review of the Literature , 2005, Pharmacotherapy.

[15]  S. Köklü,et al.  Probable Sulbactam/Ampicillin–Associated Prolonged Cholestasis , 2004, The Annals of pharmacotherapy.

[16]  R. Andrade,et al.  Drug-induced hepatotoxicity , 2003, The New England journal of medicine.

[17]  R. Kumashiro,et al.  Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting. , 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

[18]  P. Zapater,et al.  A New Poisson and Bayesian-Based Method to Assign Risk and Causality in Patients with Suspected Hepatic Adverse Drug Reactions , 2002, Drug safety.

[19]  M. Rathore,et al.  Higher occurrence of hepatotoxicity and rash in patients treated with oxacillin, compared with those treated with nafcillin and other commonly used antimicrobials. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  D. Larrey Drug-induced liver diseases. , 2000, Journal of hepatology.

[21]  N. Kaplowitz,et al.  Mechanisms of drug-induced liver disease. , 1995, Gastroenterology clinics of North America.

[22]  I. Wanless,et al.  Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim-sulfamethoxazole. , 1994, The American journal of gastroenterology.

[23]  A. Flahault,et al.  Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. , 1993, Journal of clinical epidemiology.

[24]  G. Danan,et al.  Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. , 1993, Journal of clinical epidemiology.

[25]  C. Bénichou Criteria of drug-induced liver disorders. Report of an international consensus meeting. , 1990, Journal of hepatology.

[26]  H. Zimmerman,et al.  Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver , 1978 .